Crystal structure of pirfenidone (5-methyl-1-phenyl-1 H-pyridin-2-one): an active pharmaceutical ingredient (API)

Acta Crystallogr E Crystallogr Commun. 2019 Jun 11;75(Pt 7):984-986. doi: 10.1107/S2056989019006418. eCollection 2019 Jul 1.

Abstract

The crystal structure of pirfenidone, C12H11NO [alternative name: 5-methyl-1-phenyl-pyridin-2(1H)-one], an active pharmaceutical ingredient (API) approved in Europe and Japan for the treatment of Idiopathic pulmonary fibrosis (IPF), is reported here for the first time. It was crystallized from toluene by the temperature gradient technique, and crystallizes in the chiral monoclinic space group P21. The phenyl and pyridone rings are inclined to each other by 50.30 (11)°. In the crystal, mol-ecules are linked by C-H⋯O hydrogen bonds involving the same acceptor atom, forming undulating layers lying parallel to the ab plane.

Keywords: active pharmaceutical ingredient (API); crystal structure; hydrogen bonding; idiopathic pulmonary fibrosis (IPF); pirfenidone.

Grants and funding

This work was funded by Università degli Studi di Milano grant PSR2018_DIP_005_COLOMBO_VALENTINA to Valentina Colombo.